Discovery Engine

The quest for what’s next in oncology

For us, next-generation drug discovery in oncology takes courage and persistence, the courage to embrace and invest in areas of uncertainty and the persistence to seek out and pursue innovative science.

This unique approach to research has resulted in a robust and diverse pipeline that isn’t limited to one cancer type or mechanism. All of our compounds push the boundaries of biology—aiming to propel cancer treatment forward.

Mechanisms we are currently exploring include:

ROS
generation
Kinase
inhibition
Cancer
vaccination
TLR
agonism
ACVR1
inhibition
PIM
inhibition
PKM2
activation

Discovery and the promise of purposeful science

David J Bearss, Ph.D., Chief Scientific Officer and Global Head of Research

Excellence in global collaboration

As one united team, we work together across geographies. Collectively, we bring together distinct proficiencies and strengths that are critical to inspiring innovation. In the past decade, our team has advanced and expanded our oncology pipeline to include multiple compounds and even more early discovery programs.

United in mission and mindset

Our team is relentless in their pursuit of life-changing discoveries. Through purposeful science, we aim to uncover the most impactful treatments of tomorrow.